Volume 9, Issue 1 (Vol.9 No.1 Apr 2020)                   rbmb.net 2020, 9(1): 64-70 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Sadabadi F, Gholoobi A, Heidari-Bakavol A, Mouhebati M, Javandoost A, Asadi Z, et al et al . Decreased Threshold of Fasting Serum Glucose for Cardiovascular Events: MASHAD Cohort Study. rbmb.net. 2020; 9 (1) :64-70
URL: http://rbmb.net/article-1-448-en.html
Department of Biostatistics & Epidemiology, School of Health, Management & Social Determinants of Health Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Abstract:   (329 Views)
Background: Cardiovascular disease (CVD) is the leading cause of morbidity and mortality globally, and specifically in Iran. Generally, diabetes mellitus is the result of impaired glucose tolerance which together with dyslipidemia are considered as important risk factors of CVD. The aim of this study was to determine the relationship between fasting serum glucose (FSG), lipid profile and CVD endpoints, and to establish an optimal FSG cut-off in the MASHAD cohort study after nearly 6 years of follow-up.
Methods: All the participants of MASHAD study were followed up for 6 years to determine their cardiovascular status. FSG, fasting lipids, and physical examinations were all recorded. To identify the optimal cut- off point of FSG, we carried out receiver operating curve (ROC) analysis
Results: We determined MASHAD cutoff point of blood glucose as 90 mg/dl predicting the CVD outcome. The sensitivity and specificity of the FSG criterion were 54.34% and 71.68%, respectively. The AUC was 0.665 (95% CI 0.656-0.675, P< 0.0001). The adjusted hazard ratio show that FSG is associated with 2.34 increase in CVD risk using MASHAD cutoff point (HR 2.34, 95% 1.73–3.17, P< 0.001).
Conclusions: These findings suggest that not only FSG and lipid profile are related to CVD outcome in the MASHAD study, but also elevated fasting glucose levels is strongly associated with cardiovascular events in this population. Besides, the fasting glucose at a threshold of 90 mg/dl can be used for screening cardiovascular events among the Iranian population.
Full-Text [PDF 180 kb]   (110 Downloads)    
Type of Article: Original Article | Subject: Biochemistry
Received: 2020/01/14 | Accepted: 2020/02/2 | Published: 2020/05/19

References
1. Nejat A, Mirbolouk M, Mohebi R, Hasheminia M, Tohidi M, Saadat N, et al. Changes in lipid measures and incident coronary heart disease: Tehran Lipid & Glucose Study. Clin biochem. 2014;47(13-14):1239-44. [DOI:10.1016/j.clinbiochem.2014.03.004] [PMID]
2. Emerging Risk Factors Collaboration; N Sarwar, P Gao, S R Kondapally Seshasai, R Gobin, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375(9733):2215-22. [DOI:10.1016/S0140-6736(10)60484-9]
3. Mongraw-Chaffin M, LaCroix AZ, Sears DD, Garcia L, Phillips LS, Salmoirago-Blotcher E, et al. A prospective study of low fasting glucose with cardiovascular disease events and all-cause mortality: The Women's Health Initiative. Metabolism. 2017;70:116-124. [DOI:10.1016/j.metabol.2017.02.010] [PMID] [PMCID]
4. Kim H-K, Kim C-H, Kim EH, Bae SJ, Choe J, Park J-Y, et al. Impaired fasting glucose and risk of cardiovascular disease in Korean men and women: the Korean Heart Study. Diabetes Care. 2013;36(2):328-35. [DOI:10.2337/dc12-0587] [PMID] [PMCID]
5. Esteghamati A, Zandieh A, Hafezi-Nejad N, Sheikhbahaei S, Abbasi M, Gouya MM, et al. Revising the fasting glucose threshold for detection of cardiovascular risk factors: analysing two representative population-based studies of more than 50 000 Iranians in 3 years: The National Survey of Risk Factors for Non-Communicable Diseases of Iran. Ann hum biol. 2015;42(2):150-8. [DOI:10.3109/03014460.2014.932011] [PMID]
6. Ghayour-Mobarhan M, Moohebati M, Esmaily H, Ebrahimi M, Parizadeh SMR, Heidari-Bakavoli AR, et al. Mashhad stroke and heart atherosclerotic disorder (MASHAD) study: design, baseline characteristics and 10-year cardiovascular risk estimation. Int J Public Health. 2015;60(5):561-72. [DOI:10.1007/s00038-015-0679-6] [PMID]
7. Perkins NJ, Schisterman EF. The Inconsistency of ''Optimal''Cutpoints Obtained using Two Criteria based on the Receiver Operating Characteristic Curve. Am J Epidemiol. 2006;163(7):670-5. [DOI:10.1093/aje/kwj063] [PMID] [PMCID]
8. Aschner P. New IDF clinical practice recommendations for managing type 2 diabetes in primary care. Diabetes Res Clin Pract. 2017;132:169-170. [DOI:10.1016/j.diabres.2017.09.002] [PMID]
9. Shaye K, Amir T, Shlomo S, Yechezkel S. Fasting glucose levels within the high normal range predict cardiovascular outcome. Am Heart J. 2012;164(1):111-116. [DOI:10.1016/j.ahj.2012.03.023] [PMID] [PMCID]
10. Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes care. 1997;20(4):614-20. [DOI:10.2337/diacare.20.4.614] [PMID]
11. Briel M, Ferreira-Gonzalez I, You JJ, Karanicolas PJ, Akl EA, Wu P, et al. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. Bmj. 2009;338:b92. [DOI:10.1136/bmj.b92] [PMID] [PMCID]
12. Idiopathic B, Endocrinopathies D. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes care. 2003;26 suppl 1:S5-20. [DOI:10.2337/diacare.26.2007.S5] [PMID]
13. Huang C.L, Chang H.W, Chang J.B, Chen J.H, Lin J.D, Wu C.Z, et al. Normal fasting plasma glucose predicts type 2 diabetes and cardiovascular disease in elderly population in Taiwan. QJM. 2016;109(8):515-22. [DOI:10.1093/qjmed/hcv204] [PMID] [PMCID]
14. Bao C, Zhang D, Sun B, Lan L, Cui W, Xu G, et al. Optimal cut-off points of fasting plasma glucose for two-step strategy in estimating prevalence and screening undiagnosed diabetes and pre-diabetes in Harbin, China. PloS one. 2015;10(3):e0119510. [DOI:10.1371/journal.pone.0119510] [PMID] [PMCID]

Add your comments about this article : Your username or Email:
CAPTCHA

© 2015 All Rights Reserved | Reports of Biochemistry and Molecular Biology

Designed & Developed by : Yektaweb